Analysis of Serum Markers with Regard to Treatment Procedures in Advanced Stage Prostate Cancer Patients
| Autor: | Piotr Petrasz, Sylwia Sulimiera Michalak, Edyta Wolny-Rokicka, Wojciech Krajewski, Andrzej Tukiendorf |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Male medicine.medical_specialty Apoptosis 030204 cardiovascular system & hematology Caspase 8 Risk Assessment Fas ligand 03 medical and health sciences Prostate cancer 0302 clinical medicine Antigen Clinical Research Internal medicine medicine Humans Receptors Tumor Necrosis Factor Type II Receptor Aged Neoplasm Staging Prostatectomy business.industry Prostatic Neoplasms Apoptosis Inducing Factor General Medicine Hyperplasia DNA Methylation Prostate-Specific Antigen medicine.disease Prognosis Caspase 9 P-Selectin Receptors Tumor Necrosis Factor Type I 030220 oncology & carcinogenesis Tumor necrosis factor alpha Neoplasm Recurrence Local business Cell-Free Nucleic Acids Biomarkers |
| Zdroj: | Medical Science Monitor : International Medical Journal of Experimental and Clinical Research |
| ISSN: | 1643-3750 |
| Popis: | BACKGROUND Biomarkers predicting the efficacy of treatment for locally limited prostate cancer are greatly needed. This knowledge could improve the classification of patients for different methods of treatment and enable better recognition of groups with higher risk of biological recurrence. We prospectively assessed serial blood levels of apoptotic biomarkers and correlated them with response to treatment and clinical factors. MATERIAL AND METHODS Blood was collected from 25 patients with prostate cancer before and after surgery, 16 healthy volunteers with benign prostatic hyperplasia (BPH), and 14 patients with metastasized disease. Immunoenzymatic methods were used to determine circulating apoptotic and inflammatory mediators, including tumor necrosis factor alpha (TNF-alpha), type I receptor (TNFRI), and type II receptor (TNFRII); FAS ligand (FasL); TNF-related apoptosis-inducing ligand (TRIAL); caspase 8 (Cas8); caspase 9 (Cas9); DNA methylation (metDNA); P-selectin; and high-sensitivity C-reactive protein. The total circulating fragments of cell-free DNA (cfDNA) were measured directly in serum. RESULTS Peripheral serum prostate-specific antigen increased rapidly together with cfDNA. A negative correlation was noted between tumor volume and TNFRI and TNFRII. Postsurgery P-selectin level was decreased, and metDNA and TNFRII levels were increased. Three comparisons were made between patient groups: surgical vs. BPH; surgical vs. palliative; and palliative vs. BPH. TNFRI, TNFRII, metDNA, P-selectin, Cas8, and FasL were shown to have significant roles. CONCLUSIONS The study indicated significant roles for cfDNA, both TNF receptors, metDNA, and P-selectin as serum biomarkers in patients with prostate cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|